Yuhan Corp banner

Yuhan Corp
KRX:000100

Watchlist Manager
Yuhan Corp Logo
Yuhan Corp
KRX:000100
Watchlist
Price: 95 100 KRW -1.45% Market Closed
Market Cap: ₩7.7T

Yuhan Corp
Operating Expenses

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Yuhan Corp
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Yuhan Corp
KRX:000100
Operating Expenses
-₩625.5B
CAGR 3-Years
-9%
CAGR 5-Years
-6%
CAGR 10-Years
-9%
SK Biopharmaceuticals Co Ltd
KRX:326030
Operating Expenses
-₩459.9B
CAGR 3-Years
-11%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Operating Expenses
-₩626.6B
CAGR 3-Years
-4%
CAGR 5-Years
-3%
CAGR 10-Years
1%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Operating Expenses
-₩100.9B
CAGR 3-Years
-9%
CAGR 5-Years
-3%
CAGR 10-Years
-7%
M
Mezzion Pharma Co Ltd
KOSDAQ:140410
Operating Expenses
-₩18.2B
CAGR 3-Years
7%
CAGR 5-Years
-4%
CAGR 10-Years
-4%
C
Caregen Co Ltd
KOSDAQ:214370
Operating Expenses
-₩31.8B
CAGR 3-Years
-19%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
No Stocks Found

Yuhan Corp
Glance View

Market Cap
7.7T KRW
Industry
Pharmaceuticals

In the bustling landscape of South Korea's pharmaceutical industry, Yuhan Corp. stands out as a venerable institution with a rich legacy and a forward-thinking approach. Founded in 1926, Yuhan has carved out a respected space in the market through its commitment to developing, manufacturing, and distributing a wide array of pharmaceutical and healthcare products. The company operates across multiple segments, focusing on prescription drugs, over-the-counter medications, and consumer health products that cater to various needs from chronic diseases to everyday health care. Yuhan’s product portfolio includes a combination of in-house innovations and collaborations with global leaders, which has allowed it to build a sustainable revenue stream and secure a substantial market share both domestically and internationally. At the core of Yuhan's business model is the strategic integration of research and development with commercial prowess. The company invests significantly in R&D to stay ahead of industry trends and meet evolving patient needs. This focus on innovation is complemented by strategic partnerships and licensing agreements with international pharmaceutical corporations, allowing Yuhan to introduce groundbreaking therapies to the Korean market. Additionally, Yuhan capitalizes on its robust distribution network, ensuring wide accessibility and penetration of its products. These efforts not only reinforce Yuhan’s position as a leader in the pharmaceutical sector but also fuel its steady financial growth, providing a reliable return on investment through a combination of direct sales and strategic partnerships.

Intrinsic Value
68 830.41 KRW
Overvaluation 28%
Intrinsic Value
Price ₩95 100

See Also

What is Yuhan Corp's Operating Expenses?
Operating Expenses
-625.5B KRW

Based on the financial report for Dec 31, 2025, Yuhan Corp's Operating Expenses amounts to -625.5B KRW.

What is Yuhan Corp's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-9%

Over the last year, the Operating Expenses growth was 1%. The average annual Operating Expenses growth rates for Yuhan Corp have been -9% over the past three years , -6% over the past five years , and -9% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett